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To date, there have been 35 reports of immuno-CPI-induced T1DM in literature. †, Glucocorticoid was administered in all 7 patients who developed immune-CPIs-induced T1DM. T1DM could not be reversed in any of the patients. immuno-CPIs, immuno-checkpoint inhibitors; T1DM, type 1 diabetes mellitus; NIV, nivolumab; IPI, ipilimumab; PEM, pembrolizumab; PDL1 antibody, programmed cell death-1 ligand; ATE, atezolizumab; DKA, diabetic ketoacidosis; GC; glucocorticoid; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; RCC, renal cell carcinoma; HL, Hodgkin's lymphoma; NIV, nivolumab; IPI, ipilimumab; PEM; pembrolizumab, ATE, atezolizumab; N/A, not applicable; GAD, glutamic acid decarboxylase; IA2, insulinoma-associated antigen-2; IAA, insulin autoantibody; ZnT8, zinc transporter 8; ICA, islet cell antibody; N/A, not applicable.
